一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 证券代码：600587 证券简称：新华医疗 公告编号：临 2025-021 山东新华医疗器械股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 3 日 9 点 00 分 召开地点：淄博市高新技术产业开发区泰美路 7 号新华医疗科技园办公楼三 楼会议室 股东大会召开日期：2025年6月3日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 3 日 至2025 年 6 月 3 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开 ...

山东新华医疗器械股份有限公司 第十一届监事会第十八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、 误导性陈述或者重大遗漏负连带责任。 一、监事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届监事会第十八次会议于 2025 年 4 月 18 日以通讯和书面方式发出通知，据此 通知，会议于 2025 年 4 月 28 日在公司三楼会议室召开，应到监事 3 名，实到 3 名。会议由监事会主席牟乐海先生召集和主持，符合《公司法》和《公司章程》 规定。 证券代码：600587 证券简称：新华医疗 编号：临 2025-012 二、监事会会议审议情况 （一）审议通过《2024 年年度报告全文及摘要》和《2025 年第一季度报告》， 并对公司 2024 年年度报告和 2025 年第一季度报告发表审核意见 公司监事会根据《证券法》、《公开发行证券的公司信息披露内容与格式准 则第 2 号——年度报告的内容与格式（2021 年修订）》及最新修订征求意见稿、 《公开发行证券的公司信息披露编报规则第 15 号——财务报告的一般规定 （2023 年修订）》 ...

第十一届董事会第十八次会议决议公告 证券代码：600587 证券简称：新华医疗 编号：临 2025-011 山东新华医疗器械股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第十八次会议于 2025 年 4 月 18 日以书面或通讯方式通知全体董事， 据此通知，会议于 2025 年 4 月 28 日在公司三楼会议室召开。会议以现场与通讯 相结合的方式召开，会议应到董事 11 名，实到 11 名，公司监事和高级管理人员 列席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司 章程》的规定。 二、董事会会议审议情况 （一）审议通过《2024 年年度报告全文及摘要》 董事会审计委员会审议通过了《2024 年年度报告全文及摘要》。 本议案尚需提交股东大会审议。 详见公司于 2025 年 4 月 30 日在上海证券交易所网站（www.sse.com.cn）披 露的《新华医疗 2024 年年度报告全文及摘要》。 表决结果：同意 11 ...

证券代码：600587 证券简称：新华医疗 编号：临 2025-011 山东新华医疗器械股份有限公司 关于 2024 年度利润分配预案和提请股东大会授权董事会制 定 2025 年中期分红方案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中 的任何虚假记载、误导性陈述或者重大遗漏承担连带责任。 重要内容提示： 每股分配比例：山东新华医疗器械股份有限公司（以下简称"公司"或 "新华医疗"）拟向全体股东每 10 股派发现金红利 2.50 元（含税）。不进行资本 公积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的，公司拟维持现金派发每股分配比例不变，相应调整现金派发总金额， 并将在相关公告中披露。 公司不会触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以 下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 一、基本情况 （一）公司 2024 年度利润分配预案 经天职国际会计师事务所（特殊普通合伙）审计，新华医疗 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,307,531,823.28, a decrease of 8.74% compared to ¥2,528,538,840.43 in the same period last year[4]. - Net profit attributable to shareholders was ¥160,455,800.07, down 23.97% from ¥211,036,820.12 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥157,702,901.57, reflecting a decline of 24.53% compared to ¥208,965,933.49 in the previous year[4]. - The basic and diluted earnings per share were both ¥0.27, a decrease of 22.86% from ¥0.35 in the same period last year[4]. - The weighted average return on equity decreased to 2.09%, down 0.78 percentage points from 2.87% year-on-year[4]. - Total operating revenue for Q1 2025 was CNY 2,307,531,823.28, a decrease of 8.7% from CNY 2,528,538,840.43 in Q1 2024[18]. - Net profit for Q1 2025 was CNY 161,227,589.00, a decline of 25.1% compared to CNY 215,024,150.02 in Q1 2024[19]. - Earnings per share for Q1 2025 was CNY 0.27, down from CNY 0.35 in Q1 2024[20]. - The company reported a total comprehensive income of CNY 161,227,589.00 for Q1 2025, compared to CNY 215,024,150.02 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥15,324,351,008.59, a decrease of 1.30% from ¥15,526,375,082.77 at the end of the previous year[5]. - The company's current assets totaled CNY 9,059,086,874.27, down from CNY 9,366,020,874.15, indicating a decrease of about 3.3%[14]. - The total liabilities decreased to CNY 6,848,384,341.13 from CNY 7,237,038,074.90, reflecting a reduction of approximately 5.4%[15]. - Total liabilities amounted to CNY 7,155,288,798.36, a decrease from CNY 7,543,748,934.23 in the previous period[16]. - The company's long-term equity investments increased to CNY 1,518,261,716.52 from CNY 1,506,671,275.58, reflecting a growth of about 0.8%[15]. - The total current liabilities amounted to CNY 6,848,384,341.13, which is a significant portion of the total liabilities[15]. Cash Flow - The net cash flow from operating activities was -¥163,624,921.28, an improvement from -¥213,902,750.72 in the same period last year[4]. - Cash received from sales of goods and services in Q1 2025 was CNY 2,039,406,999.49, a slight decrease from CNY 2,070,468,159.18 in Q1 2024[22]. - The net cash flow from operating activities was -$163.62 million, compared to -$213.90 million in the previous period, indicating an improvement of approximately 23.5%[23]. - Total cash inflow from operating activities was $2.11 billion, while cash outflow was $2.28 billion, resulting in a net cash flow of -$163.62 million[23]. - Cash inflow from investment activities was $1.45 million, while cash outflow was $187.67 million, leading to a net cash flow of -$186.21 million[23]. - Cash inflow from financing activities was $455.10 million, with cash outflow totaling $432.62 million, resulting in a net cash flow of $22.48 million[24]. - The total cash and cash equivalents at the end of the period was $2.44 billion, down from $2.65 billion in the previous period[24]. - Payments to employees amounted to $514.46 million, reflecting a decrease from $537.90 million in the previous period[23]. Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.50% to ¥7,786,792,401.82 from ¥7,597,127,229.99 at the end of the previous year[5]. - Total equity attributable to shareholders increased to CNY 7,786,792,401.82 from CNY 7,597,127,229.99[16]. Operational Insights - The decline in revenue was primarily due to decreased sales in the medical trading segment[8]. - The company reported non-recurring gains of ¥2,752,898.50, after accounting for tax and minority interests[8]. - Research and development expenses increased to CNY 93,857,263.18 in Q1 2025, up from CNY 83,305,119.71 in Q1 2024, reflecting a focus on innovation[19]. - The company reported no significant changes in the shareholder structure or participation in margin financing activities during the reporting period[12]. Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[25].

Financial Performance - The company's operating revenue for 2024 reached RMB 10,020,618,625.09, a slight increase of 0.09% compared to RMB 10,011,868,423.40 in 2023[23] - Net profit attributable to shareholders for 2024 was RMB 691,609,558.03, representing a growth of 5.75% from RMB 653,997,275.95 in 2023[23] - The net profit after deducting non-recurring gains and losses was RMB 623,195,651.23, showing a marginal increase of 0.60% compared to RMB 619,448,862.20 in 2023[23] - Cash flow from operating activities decreased significantly by 56.24% to RMB 450,733,485.54 from RMB 1,030,114,479.17 in 2023[23] - The company's total assets at the end of 2024 were RMB 15,526,375,082.77, a decrease of 0.41% from RMB 15,590,329,775.23 in 2023[23] - The net assets attributable to shareholders increased by 3.81% to RMB 7,597,127,229.99 from RMB 7,318,625,200.44 in 2023[23] - Basic earnings per share for 2024 were RMB 1.14, up 3.64% from RMB 1.10 in 2023[25] - The weighted average return on net assets for 2024 was 9.29%, a decrease of 0.18 percentage points from 9.47% in 2023[25] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 151,669,479.75[8] - The cash dividend amount for the year is CNY 151,669,479.75, representing 21.93% of the net profit attributable to ordinary shareholders[155] - The cumulative cash dividend over the last three accounting years is CNY 455,041,722.60, with an average cash dividend ratio of 73.96%[157] Research and Development - The company launched over 100 new products, including key innovations in high-temperature sterilization and 3D imaging technologies[35] - The company has signed 60% more external technology cooperation projects compared to the previous year, enhancing innovation capabilities[36] - The company is recognized as a national key high-tech enterprise and has established multiple provincial-level R&D platforms, contributing to over 100 new key technology innovation projects annually[43] - The company is focusing on upgrading existing products and developing new automated devices, with a registration certificate for fully automated glycosylated hemoglobin equipment obtained in August 2024[47] - The company is committed to technology innovation as a primary driver for growth, emphasizing the importance of talent and innovation in its strategic development[53] Market Expansion and Strategy - The company is expanding its overseas market presence, with successful operations in Indonesia and Saudi Arabia[36] - The company has successfully entered high-end markets such as the EU, achieving its first export sales of multiple products, significantly enhancing its overseas market visibility and share[37] - The company is actively pursuing international market expansion and product certification to enhance its competitive position globally[113] - The company is focusing on market segmentation and precision marketing by conducting in-depth market research and data analysis to tailor marketing strategies based on customer types and consumption habits[112] Operational Efficiency and Cost Management - The company has implemented a VMI inventory management model with core suppliers, effectively reducing internal inventory levels and mitigating supply chain fluctuations[53] - The company has implemented comprehensive cost control measures and optimizing resource allocation to enhance operational efficiency[115] - The company has established partnerships with key industry players to enhance distribution channels and improve market reach[131] Environmental Responsibility - The company invested 1,494,700 CNY in environmental protection during the reporting period[170] - The company has established an environmental management system compliant with GB/T24001-2016 standards to ensure legal and compliant environmental management activities[183] - The company has implemented a clean production approach in its park to promote energy conservation and emission reduction[183] - The company achieved a reduction of 4,776.26 tons in carbon dioxide equivalent emissions through various carbon reduction measures, including a 8.2MW photovoltaic power generation system[184] Corporate Governance - The company ensures compliance with shareholder meeting procedures, safeguarding shareholders' rights and maintaining equal status among all shareholders[122] - The board of directors consists of four independent directors, representing one-third of the board, ensuring the protection of minority shareholders' interests[122] - The company has established various committees, including an audit committee and a remuneration committee, to enhance decision-making processes and reduce risks[122] Legal and Compliance - The company has ongoing litigation with 3M Innovation Co., Ltd. regarding patent infringement, with a settlement amount of RMB 20 million[196] - The company has committed to transparency in its financial disclosures and compliance with relevant regulations[190] - The company has not reported any significant lawsuits or arbitration matters that could materially affect its financial position, aside from the ongoing patent case[195] Employee and Management - The company has a total of 8,135 employees, with 4,132 in the parent company and 4,003 in major subsidiaries[147] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 11.33 million yuan[135] - The management team has a strong background in the medical and financial sectors, enhancing the company's strategic direction[129]

山 东 新 华 医 疗 器 械 股 份 有 限 公 司 募 集 资 金 存 放 与 实 际 使 用 情 况 鉴 证 报 告 天 职 业 字 [2025]12127 号 录 ll 募集资金存放与实际使用情况鉴证报告 ] 关于公司募集资金存放与实际使用情况的专项报告 - 3 您可使用手机"扫一扫"或进入"注册会计师行业统一照管平台（http://acc.mb.geps.cn）"进行查查 您可使用手机"扫一扫"或差入"注册会计师行业统一照管平台（http://accomb.gov.cn）"进行查查 "我们 募集资金存放与实际使用情况鉴证报告 天职业字[2025]12127 号 山东新华医疗器械股份有限公司全体股东: 我们审核了后附的山东新华医疗器械股份有限公司(以下简称"新华医疗")《关于公司募 集资金存放与实际使用情况的专项报告》。 一、管理层的责任 新华医疗管理层的责任是按照中国证监会《上市公司监管指引第2号 -- 上市公司募集资 金管理和使用的监管要求》、上海证券交易所颁布的《上海证券交易所上市公司自律监管指引 第 1 号 -- 规范运作》及相关格式指引规定编制《关于公司募集资金存放与实际使用情况的专 项报告 ...

中信建投证券股份有限公司 关于山东新华医疗器械股份有限公司 2024 年持续督导年度报告书 | 保荐人名称：中信建投证券股份 | 被保荐上市公司名称：山东新华医疗器械股份 | | --- | --- | | 有限公司 | 有限公司 | | 保荐代表人姓名：田斌 | 联系方式：010-56051821 联系地址：北京市朝阳区景辉街 16 号院 1 号楼 | | | 泰康集团大厦 | | 保荐代表人姓名：欧阳志成 | 联系方式：010-56051821 | | | 联系地址：北京市朝阳区景辉街 号院 号楼 16 1 | | | 泰康集团大厦 | 经中国证券监督管理委员会《关于核准山东新华医疗器械股份有限公司非公 开发行股票的批复》（证监许可[2022]1223 号）核准，山东新华医疗器械股份有 限公司（以下简称"新华医疗"）非公开发行人民币普通股（A 股）54,900,098 股，募集资金总额为人民币 1,283,564,291.24 元，扣除各项不含税发行费用人民 币 7,325,377.45 元后，实际募集资金净额为人民币 1,276,238,913.79 元，上述资 金已于 2023 年 2 月 14 日全 ...

中信建投证券股份有限公司 关于山东新华医疗器械股份有限公司 2024 年度日常关联交易和预计 2025 年度日常关联交易 的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券""保荐人"）作为山 东新华医疗器械股份有限公司（以下简称"新华医疗""公司"）非公开发行股票 的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》等 相关法规和规范性文件的要求，对新华医疗 2024 年度日常关联交易执行情况及 2025 年度日常关联交易预计的事项进行了核查，具体情况如下： 一、日常关联交易基本情况 （一）2024 年日常关联交易的预计和执行情况 单位：万元 | 关联交易类别 | 关联人 | 上年（前次）预 计金额 | 上年（前次）实 际发生金额 | 预计金额与实际发生金 额差异较大的原因 | | --- | --- | --- | --- | --- | | 向 关 联 方 销 售 药 | 山 东 健 康 权 | | | 山东健康正在对下属医 | | 品、器械、设备等 | 属 医 疗 机 构 及子公司 | 21,000. ...

山 东 新 华 医 疗 器 械 股 份 有 限 公 司 审计报告 天 职 业 字 [2025]12133 号 录 审计报告 - l 2024 年度财务报表- -7 2024 年度财务报表附注— -19 您可使用手机"扫一扣"或遗入"注册会计师行业绩"涨食是否由具石频业许师的会计师事务所出具 您可使用手机"扫一扫"或遗入"注册会计师行业统一流管平台（http://ac.mof.gov.cn）"龙行查_ "" 目 审计报告 天职业字[2025]12133 号 山东新华医疗器械股份有限公司全体股东: 一、审计意见 我们审计了山东新华医疗器械股份有限公司(以下简称"新华医疗")财务报表,包括 2024 年 12 月 31 日的合并及母公司资产负债表、2024年度的合并及母公司利润表、合并及母公司现 金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了新 华医疗 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营成果和 现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了 ...